SeraCare Introduces New Hepatitis C ACCUVERT Seroconversion Panels and Anti-Herpes ACCUSET Performance Panel
New panels provide manufacturers with material from a variety of donor genotypes and recent collection periods.
Milford, Massachusetts (PRWEB) May 15, 2013
SeraCare Life Sciences, a provider of high quality biological materials that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, announced it has launched three new ACCUVERT seroconversion panels and one new ACCUSET performance panel. These product additions expand the company´s offerings that assist in vitro diagnostics manufacturers in challenging new and existing assays.
“As new therapeutics in the drug discovery pipeline are increasingly tailored by genotype, SeraCare is responding with ACCUVERT seroconversion panels that provide the diverse, genotype-specific material our customers require as part of their rigorous regulatory submission process,” said Kim Anderson, Product Manager, IVD Research Business Unit at SeraCare. “We´re equally committed to building out our industry-leading line of ACCUSET performance panels targeted at the infectious disease areas of greatest interest to researchers today.”
SeraCare´s three new Hepatitis C ACCUVERT seroconversion panels provide manufacturers with material from a variety of donor genotypes and recent collection periods. Each panel demonstrates how a single donor responds in the presence of the disease during the collection period, with a graphical depiction of seroconversion. Product data sheets also offer comparative data that is valuable in reviewing test results from a number of industry leading assays. The new Hepatitis C ACCUVERT seroconversion panels include:
- HCV Seroconversion Panel PHV924, providing undiluted plasma samples from a single male donor of genotype 2b, drawn over an 88-day period in 2008
- HCV Seroconversion Panel PHV925, providing undiluted plasma samples from a single male donor of genotype 1a, drawn over a 27-day period in 2008
- HCV Seroconversion Panel PHV926, providing undiluted plasma samples from a single male donor of genotype 3a, drawn over a 14-day period in 2009
SeraCare also released a new Anti-Herpes Mixed Titer Performance Panel of naturally occurring, well-characterized plasma and serum specimens for use in developing, evaluating and troubleshooting anti-HSV 1/2, anti-HSV 1 and anti-HSV 2 assays. The 21-member panel represents a broad range of reactivity to anti-HSV 1/2 IgG and IgM markers, from negative to strongly positive. Comprehensive test results for multiple industry assays are provided for comparative purposes.
The SeraCare line of ACCUVERT seroconversion panels — designed to help diagnostics manufacturers and clinical labs evaluate, monitor and troubleshoot test and staff performance — includes a variety of options for HIV, Hepatitis A, Hepatitis B, Hepatitis C and West Nile Virus. SeraCare ACCUSET performance panels encompass a broad range of highly characterized, disease state patient samples designed for use with most instrument platforms and test methods.
SeraCare´s new Hepatitis C ACCUVERT seroconversion panels and Anti-Herpes ACCUSET performance panel are available immediately worldwide. For more information, contact SeraCare Customer Service at 1-800-676-1881 or visit http://www.seracare.com.
About SeraCare Life Sciences, Inc.
SeraCare, a portfolio company of Linden Capital Partners, partners with diagnostics researchers, IVD manufacturers and clinical laboratories to shape the future of medical diagnostics. Our innovative portfolio includes ACCURUN® quality controls, research panels, SeraCon® processed biological materials, specialty human blood products and characterized disease state materials. SeraCare helps bridge the gap between today´s diagnostic solutions and tomorrow´s emerging technologies for molecular diagnostics, next generation sequencing and companion diagnostics. For more information, visit http://www.seracare.com.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden’s strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden currently has investments in middle market platforms in the products, distribution, and services segments of healthcare. For additional information about Linden, please refer to the firm’s website at http://www.lindenllc.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/5/prweb10734750.htm